International Symposium

The International Symposium for Tissue Phenomics

EVENT DATE: Oct 17 - Oct 18, 2014
EVENT HOST: Definiens
EVENT LOCATION: San Francisco, California
EVENT WEB LINK: Event URL Coming Soon

At the 2014 International Symposium for Tissue Phenomics™, attendees enjoyed expert presentations on immuno-oncology and big data, valuable panel discussions, and excellent networking with peers and other industry experts.


  • Keynote addresses by Nobel Laureate Dr. Gerd Binnig and Dr. Carlo Bifulco
  • Thought-leading presentations by industry experts
  • Extensive networking with peers and experts in cancer diagnostics and Tissue Phenomics

Tissue Phenomics experts and key opinion leaders shared their insights on:

  • Turning tissue images into big data for robust correlation to clinical outcomes.
  • How immuno-oncology is accelerating by using quantitative spatial analysis of the tumor microenvironment.
  • Using Tissue Phenomics to find new markers for stratifying patient populations.


Tissue Phenomics – A Novel Big Data Approach in Pathology
Dr. Gerd Binnig, Nobel Laureate and Chief Technology Officer, Definiens, Munich, Germany

Prognostic and Predictive Significance of the Immunological Tumor Environment
Dr. Dirk Jäger, Director Medical Oncology, National Center for Tumor Diseases (NCT), University Medical Center Heidelberg, Heidelberg, Germany

COIN-ing Potential Clinically Translatable Markers in Metastatic Colorectal Cancer Through Tissue Phenomics
Dr. Ryan Hutchinson, Fellow in Molecular Pathology, Department of Pathology, Melbourne and Centre for Translational Pathology, University of Melbourne, Melbourne, Australia

Improving Therapy-Relevant Breast Cancer Protein Profiling Using Quantitative Immunofluorescence
Dr. Amy Ryder Peck, Senior Research Scientist, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Applying Tissue Phenomics to Colorectal Clinical Questions
Peter Caie, Senior Research Fellow, University of St. Andrews, Scotland

Novel Patient Stratification and Predictive Imaging Biomarkers for Development of Oncology Therapies
Dr. Belma Dogdas, Associate Principal Scientist, Merck, Rahway, New Jersey, USA

Use of Computer Tumor Tissue Imaging Algorithms to Assess the Role of Microenvironment in Melanoma Brain Metastases
Dr. Stergios Moschos, Clinical Associate Professor of Medicine The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Tissue Phenomics: From Biomarker Discovery to Clinical Diagnostic Assay Commercialization
Dr. Thomas Nifong, Executive Vice President, Diagnostic Tests, Definiens, Boston, Massachusetts, USA

Tissue Quality and Clinical Data: The Bottleneck for Drug and Biomarker Development
Dr. Hartmut Juhl, Chief Executive Officer, Indivumed GmbH, Hamburg, Germany

Measurement of Target Engagement and Pharmacodynamic Response to Investigational Anti-Cancer Agents in Phase 1 Clinical Trials
Dr. Robert J. Kinders, Senior Principal Scientist and Head, Pharmacodynamics, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA

Development of an Encapsulated Cell Replacement Therapy for Diabetes
Dr. Olivia G. Kelly, Director, Cell Biology, ViaCyte, Inc., San Diego, California, USA

Imaging and Analysis of RNA Biomarkers In Situ via RNAscope and SpotStudio
Dr. Xiao-Jun Ma, Chief Scientific Officer, Advanced Cell Diagnostics, Hayward, California, USA

Immunoscore / Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients for Clinical Trials
Dr. Carlo Bifulco, Medical Director, Oncologic Molecular Pathology and Pathology Informatics, Director, Translational Molecular Pathology, Providence Oregon Regional Laboratory & Earle A. Chiles Research Institute, Providence Health & Services, Portland, Oregon, USA

Immune Landscape and Immunoscore in the Era of Cancer Immunotherapies
Dr. Jérôme Galon, Research Director, INSERM, Head of Integrative Cancer Immunology Laboratory, INSERM, Paris, France

Implementation of Image Analysis for Biomarker Assessment of Pre-Clinical Tumor Models and Clinical Patient Samples
Dr. Belinda Cancilla, OncoMed Pharmaceuticals, Redwood City, California, USA

Companion Diagnostics: Aligning Development, Commercialization, and Market Access
Charles Mathews, Vice President, Boston Healthcare, Boston, Massachusetts, USA